Author

Robert L. Hollis

Cancer Research UKORCID 0000-0002-1390-3298Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1

Frequent Co-Authors

C. Simon HerringtoniD· 2 shared Charlie GourleyiD· 2 shared Clare Bartos· 2 shared Ian Croy· 2 shared John P. ThomsoniD· 2 shared Michael ChurchmaniD· 2 shared A. R. S. BlackiD· 1 shared Aikou OkamotoiD· 1 shared

Activity by Year

2025-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Simon HerringtonORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintNov 26, 2025

FAK inhibitor treatment systemically regulates the glioblastoma immune environment via blocking monocyte trafficking

Emily R. Webb, A. R. S. Black, Giovana Carrasco…·Valerie G. Brunton

This study shows that systemic FAK inhibition reduces immunosuppressive macrophages in glioblastoma by blocking monocyte trafficking, enhancing T cell activity and improving survival in a mouse model.

DOI 10.1101/2025.11.26.690731

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologyNature CommunicationsPeer-reviewedJul 1, 2025

Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer

Ailith Ewing, Alison M. Meynert, Ryan Silk…·Colin A M Semple

The paper identifies two divergent structural variation trajectories in HGSOC that impact patient survival and reveals novel candidate driver genes and mtDNA mutations associated with prognosis.

19 citationstop 3%

humanwhole-genome sequencing

𝕏 PostBluesky

Cancer BiologyGynecologic OncologyPeer-reviewedMay 27, 2025

Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma

Yasushi Iida, Michael Churchman, Robert L. Hollis…·John P. Thomson

This study identifies ARID1A mutation and low CD3+ TIL levels as prognostic markers for relapse in low-stage clear cell ovarian carcinoma.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky